UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of the earliest event reported): June 17, 2008
Valeant Pharmaceuticals International
(Exact name of registrant as specified in its charter)
| | | | | |
| | | | | |
| Delaware | | 1-11397 | | 33-0628076 |
| (State or other jurisdiction of | | (Commission File Number) | | (I.R.S Employer |
| incorporation or organization) | | | | Identification No.) |
One Enterprise
Aliso Viejo, California 92656
(Address of principal executive offices) (Zip Code)
(949) 461-6000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| o | | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o | | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o | | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o | | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01 Other Events
On June 17, 2008, Valeant Pharmaceuticals International issued a press release announcing that its board of directors has authorized the repurchase of an additional $100 million of its outstanding common stock under the 2007 stock repurchase program. This repurchase authorization raises the aggregate repurchase authorization to $300 million from the $200 million over a period of 24 months previously approved by the board of directors. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press release dated June 17, 2008.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | VALEANT PHARMACEUTICALS INTERNATIONAL
| |
| Date: June 17, 2008 | By: | /s/ Peter J. Blott | |
| | | Peter J. Blott | |
| | | Executive Vice President
and Chief Financial Officer | |
INDEX TO EXHIBITS
99.1 Press release dated June 17, 2008.
